Name | (5E)-3-(4-Methoxyphenyl)-5-[(5-nitro-2-thienyl)methylene]-2-thioxo-1,3-thiazolidin-4-one |
---|---|
Synonyms |
(5E)-3-(4-Methoxyphenyl)-5-[(5-nitro-2-thienyl)methylene]-2-thioxo-1,3-thiazolidin-4-one
4-Thiazolidinone, 3-(4-methoxyphenyl)-5-[(5-nitro-2-thienyl)methylene]-2-thioxo-, (5E)- CCF642 |
Description | CCF642 is a novel PDI-inhibiting compound with antimyeloma activity.The IC50 is 2.9 μmol/L.In vitro: CCF642 inhibit PDI reductase activity about 100-fold more potently than the structurally distinct established inhibitors PACMA 31 and LOC14. CCF642 causes acute ER stress in multiple myeloma cells accompanied by apoptosis-inducing calcium release.In vivo: CCF642 displayed potent efficacy in an aggressive syngeneic mouse model of multiple myeloma and prolonged the lifespan of C57BL/KaLwRij mice engrafted with 5TGM1-luc myeloma, an effect comparable to the first-line multiple myeloma therapeutic bortezomib. CCF642 can be given intravenously without injection reactions in mice with 10 mg/kg. |
---|---|
Related Catalog | |
References |
Density | 1.6±0.1 g/cm3 |
---|---|
Boiling Point | 567.3±60.0 °C at 760 mmHg |
Molecular Formula | C15H10N2O4S3 |
Molecular Weight | 378.446 |
Flash Point | 296.9±32.9 °C |
Exact Mass | 377.980255 |
LogP | 4.11 |
Vapour Pressure | 0.0±1.6 mmHg at 25°C |
Index of Refraction | 1.760 |
Storage condition | -20℃ |